

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

APPOINTMENT AND RESIGNATION OF DIRECTORS

APPOINTMENT AND RESIGNATION OF DIRECTORS

The Board is pleased to announce that Mr. Dai Yong is appointed as an executive Director of the Company with effect from 5 August 2024 while Mr. Yu Mingyang has resigned as a non-executive Director of the Company with effect from 5 August 2024.

APPOINTMENT OF DIRECTOR

The Board of Directors (the “**Board**”) of Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Dai Yong is appointed as executive director of the Company (“**Director**”) with effect from 5 August 2024. Mr. Dai is also appointed as the chief operation officer of the Group.

Mr. Dai Yong (戴勇) (“**Mr. Dai**”), aged 57, has extensive management and sales experience in medical industry. Mr. Dai graduated in July 1991 from Shanghai Medical University (now known as Fudan University School of Medicine) with a degree in medicine. After this graduation, he was assigned to work at Huashan Hospital, affiliated with Fudan University (復旦大學附屬華山醫院). He served as a marketing manager for Toshiba Medical (東芝醫療) from 1998 to 2003. From 2003 to 2009, he held various senior management positions at Siemens Healthineers China Co., Ltd. (西門子醫療中國有限公司), including general manager for the Central and East China regions, and general manager for China’s maintenance and marketing departments. From 2009 to 2024, Mr. Dai worked at Toshiba Medical Systems China Ltd. (東芝醫療系統中國有限公司) (now known as Canon Medical Systems China Ltd. (佳能系統中國有限公司)), where he served as a director of the Shanghai Office and vice president for China region, overseeing sales, marketing, operations, and channel management.

Mr. Dai is currently a standing committee member of the Shanghai Biomedical Engineering Imaging Committee (上海生物醫學工程影像專委會), president of the China Association for Integration of Traditional Chinese and Western Medicine Imaging Industry-Academia-Research Committee (中國中西醫影像協會產學研協會), vice chairman and chief operating officer of the Medical Innovation & Technology Center (MITC) (澳大利亞醫學轉化中心) in Australia, and a founding member of the Australian Home Business Alliance (澳洲家園商業聯盟).

As at the date of this announcement, save as disclosed above, Mr. Dai (i) does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) does not have, and is not deemed to have, any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”); and (iii) does not hold any position in the Company or any of its subsidiaries, nor any other directorship in listed public companies whether in Hong Kong or overseas in the last three years preceding the date of this announcement.

There is a one-year service contract entered into between the Company and Mr. Dai who is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association of the Company.

Mr. Dai will receive a fixed director’s fee of HK\$240,000 per annum. His remuneration is determined by the Board with reference to his roles and responsibilities with the Company and prevailing market conditions.

Save as disclosed above, there is no information in relation to the appointment of the Director that is required to be disclosed to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and there are no other matters that need to be brought to the attention of the shareholders of the Company.

RESIGNATION OF DIRECTOR

The Board further announces that Mr. Yu Mingyang (“**Mr. Yu**”) has tendered his resignation as a non-executive Director with effect from 5 August 2024 due to his other business commitments which require more of his time and dedication. Immediately upon the taking effect of his resignation, Mr. Yu shall also cease to be a member of the audit committee of the Board and a member of the remuneration committee of the Board.

Mr. Yu has confirmed that as at the date of this announcement, (i) he does not have any claim against the Company in respect of his resignation; (ii) he does not have any disagreement with the Board; nor (iii) there are any other matters in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to extend its warm welcome to Mr. Dai to the Board and to extend its sincere gratitude to Mr. Yu for his valuable contributions towards the Company during his tenure of office.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and Executive Director

Hong Kong, 5 August 2024

As at the date of this announcement, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping and Mr. Dai Yong; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.